^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Bladder Cancer

    Related cancers:
    15h
    Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=161, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Keytruda (pembrolizumab) • gemcitabine
    16h
    IT-TCP POS: INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Azienda Ospedaliero-Universitaria di Parma
    New trial
    18h
    Trimodality Bladder Preservation (clinicaltrials.gov)
    P=N/A, N=97, Completed, Al-Azhar University
    New trial
    21h
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov)
    P2, N=314, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    1d
    Integrated single-cell and spatial transcriptomics combined with whole-exome sequencing reveal key hub genes and epithelial heterogeneity in bladder cancer. (PubMed, Front Oncol)
    By integrating multi-omics and spatial datasets, this study reveals the epithelial heterogeneity of BLCA and identifies ABRACL and ARPC3 as key TMB-associated hub genes within EpiCs. The established risk-score model and validated functional markers provide valuable insights for future mechanistic studies and potential clinical translation in BLCA.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    1d
    Revealing the function and mechanism of piRNA-related genes in bladder cancer through single-cell sequencing and methylation analyses and construction of prognostic features based on consensus clustering. (PubMed, Curr Urol)
    This study effectively developed a 3-gene prognostic signature comprising MAPK13, INHBA, and LAMB2 using consensus clustering and multifactorial logistic regression. In addition, the functional roles and intrinsic mechanisms of piRPGs in bladder carcinogenesis were comprehensively explored using single-cell sequencing, methylation sequencing, and functional enrichment analysis.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • DDX3X (DEAD-Box Helicase 3 X-Linked) • LAMC1 (Laminin Subunit Gamma 1)
    3d
    BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P=N/A, N=4, Completed, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2027 --> Feb 2026 | Trial primary completion date: Jan 2027 --> Feb 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    FGFR3 mutation
    |
    Truseltiq (infigratinib)
    3d
    BICEP in TURBT: INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Necmettin Erbakan University
    New trial
    3d
    Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing. (PubMed, BMC Cancer)
    These findings provide preliminary evidence supporting further investigation of sex-specific approaches to BC management.
    Journal
    |
    MYBL1 (MYB Proto-Oncogene Like 1) • ONECUT2 (One Cut Homeobox 2) • SPEG (Striated Muscle Enriched Protein Kinase) • ALOX15B (Arachidonate 15-Lipoxygenase Type B)
    3d
    Oncogenic and immunological roles of LAMP5 across cancers and its potential utility in bladder cancer. (PubMed, Apoptosis)
    These findings identify LAMP5 as a multifunctional oncoprotein with both prognostic and therapeutic relevance in bladder cancer. This study provides insights into the molecular mechanisms by which LAMP5 promotes bladder cancer progression and offers potential targets for therapeutic intervention and clinical management.
    Journal • IO biomarker
    |
    FBXO11 (F-Box Protein 11)